The Food and Drug Administration has approved the first cancer immunotherapy for people with specific types of advanced bladder cancer.
Yale Oncologist Dr. Daniel Petrylak joined FOX 61 Good Day Connecticut to talk about the treatments.
The FDA has granted accelerated approval to TECENTRIQ™ (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
Marks the first FDA-approved treatment for people with a specific type of bladder cancer in more than 30 years.
